Avalyn Pharma Inc. Common Stock (AVLN) - Total Assets
Based on the latest financial reports, Avalyn Pharma Inc. Common Stock (AVLN) holds total assets worth $135.66 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Avalyn Pharma Inc. Common Stock (AVLN) share price today for real-time trading data and today's change.
Avalyn Pharma Inc. Common Stock - Total Assets Trend (2024–2025)
This chart illustrates how Avalyn Pharma Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see cash flow conversion of Avalyn Pharma Inc. Common Stock for how efficiently the company converts equity into cash flow.
Avalyn Pharma Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Avalyn Pharma Inc. Common Stock's total assets of $135.66 Million consist of 96.4% current assets and 3.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.1% |
| Accounts Receivable | $537.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Avalyn Pharma Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Avalyn Pharma Inc. Common Stock short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Avalyn Pharma Inc. Common Stock's current assets represent 96.4% of total assets in 2025, an increase from 91.9% in 2024.
- Cash Position: Cash and equivalents constituted 35.1% of total assets in 2025, up from 19.2% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Avalyn Pharma Inc. Common Stock Competitors by Total Assets
Key competitors of Avalyn Pharma Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.38 Billion |
Avalyn Pharma Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.03 | - | - |
| Quick Ratio | 11.03 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | $118.20 Million | - | - |
Avalyn Pharma Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Avalyn Pharma Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.71 |
| Latest Market Cap to Assets Ratio | 10.10 |
| Asset Growth Rate (YoY) | 19.6% |
| Total Assets | $148.88 Million |
| Market Capitalization | $1.50 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Avalyn Pharma Inc. Common Stock's assets at a significant premium (10.10x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Avalyn Pharma Inc. Common Stock's assets grew by 19.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Avalyn Pharma Inc. Common Stock (2024–2025)
The table below shows the annual total assets of Avalyn Pharma Inc. Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $148.88 Million | +19.56% |
| 2024-12-31 | $124.52 Million | -- |
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled fo… Read more